Michael Taylor

Peter MacCallum Cancer Centre — Australia

Medicine · Health Sciences

8h-index414citations52works0.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(29), Advanced Breast Cancer Therapies(28), Microtubule and mitosis dynamics(18), Glioma Diagnosis and Treatment(3), Lung Cancer Treatments and Mutations(3)

Publications52 total

Abstract GS3-06: Rb Functions as a Transcriptional Activator of ER Targets Following CDK4/6 Inhibition in Luminal Breast Cancer
Clinical Cancer Research·2026
Correction: INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Cancer Discovery·2025Open Access
Supplementary Table 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2025Open Access
Supplementary Table 1 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2025Open Access
Supplementary Figures 1-14 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2025Open Access
Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2025Open Access
Personalised prehabilitation improves functional capacity and strength in patients awaiting major surgery
Physiotherapy·2024
Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024· 1 citedOpen Access
Figure 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Supplementary Table 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Figure 3 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Data from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024· 3 citedOpen Access
Figure 3 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Supplementary Figures 1-14 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Figure 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Figure 6 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Figure 5 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Figure 5 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Figure 4 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
page 1 of 3Next →

Frequent Co-authors

Catherine Dietrich(29), Alec Trub(28), Antonio Ahn(28), Krutika Ambani(28), Kun‐Hui Lu(28), Catherine Blyth(28), Rhiannon Coulson(28), Susanne Ramm(28), John Bisi(28), Jay C. Strum(28), Patrick J. Roberts(28), Shom Goel(28), Keefe T. Chan(27), Christabella A. Mahendra(27), April C. Watt(27), Sunil Kumar Matsa(27), Lloyd H. Smith(3), Anthony H. Russell(2), Sidney Scudder(2), Walter Kinney(2)